Evidence coverage: One systematic review and meta-analysis of randomized trials across pain-VAS, WOMAC and head-to-head pain-medicine comparisons — read with its own limitations paragraph.
Crosses the clinical bar — on thin but consistent trials. certainty: Moderate (meta-analysis of 8 small randomized trials)
Pooled randomized trials show curcumin extracts reduce arthritis pain beyond placebo (VAS −2.04 on a 10-point scale) and improve WOMAC function, performing comparably to pain medicine — but the evidence base is small and partly producer-affiliated, so confidence stays moderate.
- Pain-VAS versus placebo: −2.04 (95% CI −2.85 to −1.24), P<0.00001 (source-reported)
- WOMAC versus placebo: −15.36 (95% CI −26.9 to −3.77), P=0.009 (source-reported)
- No significant difference versus pain medicine across five head-to-head comparisons (source-reported)
- Authors: trial count, sample size and quality not sufficient for definitive conclusions (source-reported)
Conflict-of-interest caution: the meta-analysis’s first author works for a curcumin manufacturer; independent replications remain the open ask. Blood-thinner interactions at supplement doses are documented pharmacologically.